 |
|
Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke
Yoshihiro Sato, MD;
Jun Iwamoto, MD;
Tomohiro Kanoko, PhD;
Kei Satoh, MD
Arch Intern Med. 2005;165:1743-1748.
Background There is a high incidence of hip fractures in patients after hemiplegic stroke. Bone mineral density is decreased on the hemiplegic side in patients after stroke, correlating with the immobilization-induced bone resorption, the degree of paralysis, and hypovitaminosis D. The purpose of this study is to evaluate the effectiveness of risedronate sodium, an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in men 65 years or older after stroke.
Methods We conducted an 18-month randomized double-blind trial. Of 280 male patients 65 years or older who were poststroke, 140 received a daily dose of 2.5 mg risedronate sodium and the other 140 received placebo. Incidence of hip fractures in the 2 groups was compared.
Results Ten patients sustained hip fractures in the placebo group, and 2 hip fractures occurred in the risedronate group. The relative risk of a hip fracture was 0.19 (95% confidence interval, 0.04-0.89). The number of patients needing the treatment was 16 (95% confidence interval, 9-32). Bone mineral density increased by 2.5% in the risedronate group and decreased by 3.5% in the placebo group (P<.001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 58.7% in the risedronate group and by 37.2% in the placebo group.
Conclusion Treatment with risedronate increases bone mineral density and reduces hip fractures in elderly men who are poststroke.
Author Affiliations: Department of Neurology, Mitate Hospital, Tagawa (Dr Sato); Department of Sport Medicine, Keio University School of Medicine, Tokyo (Dr Iwamoto); Departments of Rehabilitation Medicine (Dr Kanoko) and Vascular Biology (Dr Satoh), Hirosaki University School of Medicine, Hirosaki; Japan.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials
Jutta Martha Halbekath, Stefanie Schenk, Andreas von Maxen, Gabriele Meyer, and Ingrid Mühlhauser
Arch Intern Med. 2007;167(5):513-514.
EXTRACT
| FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials—Reply
Yoshihiro Sato
Arch Intern Med. 2007;167(5):514-515.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Risk Factors Associated With Injury Attributable to Falling Among Elderly Population With History of Stroke
Divani et al.
Stroke 2009;40:3286-3292.
ABSTRACT
| FULL TEXT
Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians
Qaseem et al.
ANN INTERN MED 2008;149:404-415.
ABSTRACT
| FULL TEXT
Osteoporosis in men.
Ott et al.
NEJM 2008;359:868-868.
FULL TEXT
Osteoporosis in Men
Khosla et al.
Endocr. Rev. 2008;29:441-464.
ABSTRACT
| FULL TEXT
Can early onset bone loss be effectively managed in post-stroke patients? An integrative review of the evidence
Marsden et al.
Age Ageing 2008;37:142-150.
ABSTRACT
| FULL TEXT
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT
| FULL TEXT
Development and Internal Validation of the Male Osteoporosis Risk Estimation Score
Shepherd et al.
Ann Fam Med 2007;5:540-546.
ABSTRACT
| FULL TEXT
Hip fractures after stroke and their prevention
Myint et al.
QJM 2007;100:539-545.
ABSTRACT
| FULL TEXT
A Single Infusion of Zoledronate Prevents Bone Loss After Stroke
Poole et al.
Stroke 2007;38:1519-1525.
ABSTRACT
| FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials--Reply
Sato
Arch Intern Med 2007;167:514-515.
FULL TEXT
Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials
Halbekath et al.
Arch Intern Med 2007;167:513-514.
FULL TEXT
|
